NCT00023764View on ClinicalTrials.gov

Bortezomib in Treating Patients With Lymphoproliferative Disorders

PHASE2CompletedINTERVENTIONAL
Enrollment

103

Participants

Timeline

Start Date

June 30, 2001

Primary Completion Date

March 31, 2009

Study Completion Date

March 31, 2009

Conditions
Recurrent Grade 1 Follicular LymphomaRecurrent Grade 2 Follicular LymphomaRecurrent Grade 3 Follicular LymphomaRecurrent Mantle Cell Lymphoma
Interventions
DRUG

bortezomib

Given IV

Trial Locations (1)

10065

Memorial Sloan-Kettering Cancer Center, New York

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00023764 - Bortezomib in Treating Patients With Lymphoproliferative Disorders | Biotech Hunter | Biotech Hunter